• SMC open account icon Open an A/C
    • Open an A/C
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Home > Markets > IPO > IPO Synopsis
Select Items

IPO Synopsis

Gland Pharma Ltd
Registered Office: Sy No 143-148 150&151 Nr Gandi,X Roads D P Pally Dundigal , Hyderabad - 500043 , Telangana , India.
Phone : 91-40-3051 0999   Fax:
Email :  
Website :
Initial public offer of 43196968 equity shares of face value of Re. 1 each ("equity shares") of Gland Pharma Limited ("Company" or "Issuer") for cash at a price of (Rs)1500 Per equity share (including a share premium of (Rs)1499 per equity share) aggregating (Rs)6479.55 crores (The "Offer") comprising a fresh issue of 8,333,333 equity shares aggregating up to (Rs)1250 crores on (The "fresh issue") and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd ("promoter selling shareholder") and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the "other selling shareholders" and collectively With the promoter selling shareholder are referred to as the "selling shareholders", and such equity shares, the "offered shares") aggregating up to (Rs)5229.55 crores (the "offer for sale"). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is (Rs)1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is (Rs)1500 per Equity Share.

Issue Money Payable On
Opens On Closes On Application Allotment
09-Nov-20 11-Nov-20 (Rs)1500.00-0.00 (Rs)0.00-0.00
Minimum Application for shares in Nos :10  Further Multiples of :10

  (Rs Cr) Lead Managers to the Issue
Project Cost 1250.00 Citigroup Global Markets India Pvt Ltd
Project Financed through Current Offer 6479.55  
Post Issue Equity Share Capital 163.28  
Issue Price (Rs)1500.00  
Funding incremental working capital requirements of the companyGeneral corporate purposes
Funding capital expenditure requirements of the company
Promoted By
Fosun Pharma Indust. Pte. Ltd  
Shanghai Fosun Pharma. Group  
Listing At
Registrar to the Issue
Link Intime India Pvt Ltd  

Follow us:

  • fb icon
  • Twitter icon
  • Linkedin
  • you tube

Disclaimer: Investment in securities and commodities market are subject to market risks, read all the related documents carefully before investing. SMC Global Securities Ltd. (CIN : U67120DL1997PLC188881): NSE INB/ INF/INE 230771431, BSE INB/INF 011343937, MSEI INB/INF 260771432, CDSL/NSDL-IN-DP-130-2015, SMC Research Analyst Registration- INH 100001849 I SMC Global Securities Ltd.: NCDEX/MCX (8200)/ NMCE/ICEX-INZ000035839 I SMC Global Securities Ltd.: PMS INP000003435 I SMC Insurance Brokers Pvt. Ltd., IRDAI Regi: No: DB 272/04, License No. 289 Valid from 28-01-2020 to 27-01-2023 I Registered Office: 11/6B, Shanti Chamber, Pusa Road, New Delhi-110005, Tel.: (011) 30111000. For any complaints email –, website:

Insurance is the subject matter of solicitation • All insurance products sold through SMC Insurance Brokers Pvt. Ltd. • Investment Banking Services provided by SMC Capitals Ltd. • Equity PMS and Wealth management services provided by SMC Global Securities Ltd. • IPOs and Mutual Funds distribution services are provided by SMC Global Securities Ltd. • Financing Services provided by Moneywise Financial Services Pvt Ltd. • Commodity broking services provided by SMC Global Securities Ltd. • Real Estate Advisory services are offered through SMC Real Estate Advisors Pvt. Ltd.


Toll-free : 1800-11-0909

Plus Minus 
Copyright ©2016 SMC. All Rights Reserved | Disclaimer | Privacy Policy | RMS Policy | Copyright| Testimonials| Sitemap| Grievance| design agency: triverse| Powered by C-MOTS Infotech (ISO 9001:2015 certified)
Open An Account

Open my trading account now!  X 

* All fields are compulsory